文献
J-GLOBAL ID:201702278183716406
整理番号:17A1389311
Osimertinibの2相II登録のための研究における前向き患者選択のためのEGFR変異解析【Powered by NICT】
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
著者 (11件):
Jenkins Suzanne
(AstraZeneca, Macclesfield, United Kingdom)
,
Chih-Hsin Yang James
(National Taiwan University Hospital, National Taiwan University Cancer Center, Taipei City, Republic of China)
,
Jaenne Pasi A.
(Dana-Farber Cancer Institute, Boston, Massachusetts)
,
Thress Kenneth S.
(AstraZeneca, Waltham, Massachusetts)
,
Yu Karen
(Roche Molecular Systems, Inc., Pleasanton, California)
,
Hodge Rachel
(AstraZeneca, Cambridge, United Kingdom)
,
Weston Susie
(AstraZeneca, Alderley Park, United Kingdom)
,
Dearden Simon
(AstraZeneca, Macclesfield, United Kingdom)
,
Patel Sabina
(AstraZeneca, Cambridge, United Kingdom)
,
Cantarini Mireille
(AstraZeneca, Alderley Park, United Kingdom)
,
Shepherd Frances A.
(Princess Margaret Cancer Centre, Toronto, Canada)
資料名:
Journal of Thoracic Oncology
(Journal of Thoracic Oncology)
巻:
12
号:
8
ページ:
1247-1256
発行年:
2017年
JST資料番号:
W3145A
ISSN:
1556-0864
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)